{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:42:40Z","timestamp":1782564160903,"version":"3.54.5"},"reference-count":36,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T00:00:00Z","timestamp":1245628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\n\t\t\t\t\t<\/jats:bold> Rhinoviruses (RVs) are responsible for the majority of acute asthma and chronic obstructive pulmonary disease (COPD) exacerbations. RVs infect the lower airways and induce the production of pro\u2010inflammatory and remodelling\u2010associated mediators. Budesonide (BUD) and formoterol (FORM) synergize in controlling asthma and COPD exacerbations; however, their effects on virus\u2010induced inflammation and remodelling are less known.<\/jats:p><jats:p><jats:bold>Objective\n\t\t\t\t\t<\/jats:bold> We investigated whether BUD and FORM synergize in suppressing RV\u2010induced inflammation and remodelling in the airways.<\/jats:p><jats:p><jats:bold>Methods\n\t\t\t\t\t<\/jats:bold>  <jats:italic>In vitro<\/jats:italic> models of RV infection of BEAS\u20102B and primary normal human bronchial epithelial (NHBE) cells were used. We assessed the effects of individual and combined drugs administered post\u2010infection, at a clinically relevant concentration range (10<jats:sup>\u22126<\/jats:sup>\u201310<jats:sup>\u221210<\/jats:sup>\u2003<jats:sc>m<\/jats:sc>), on the production of CCL5, CXCL10, CXCL8, IL\u20106 and the remodelling\u2010associated VEGF and bFGF, using ELISA and RT\u2010PCR.<\/jats:p><jats:p><jats:bold>Results\n\t\t\t\t\t<\/jats:bold> BUD effectively suppressed RV\u2010mediated induction of all mediators studied, in a concentration\u2010dependent manner. FORM alone suppressed the production of CXCL8 and bFGF. The combination of BUD and FORM had concentration\u2010dependent, additive or synergistic effects in the suppression of RV\u2010induced CCL5, CXCL8 and CXCL10 in both cell types as well as VEGF in NHBE only. Combination treatment also resulted in an enhanced suppression of RV\u2010induced IL\u20106, and CCL5 at the mRNA level as compared with BUD or FORM alone.<\/jats:p><jats:p><jats:bold>Conclusion\n\t\t\t\t\t<\/jats:bold> BUD and FORM suppress RV\u2010induced chemokines and growth factors in bronchial epithelial cells in a concentration\u2010dependent, synergistic or additive manner. These data further support the combined use of BUD and FORM in asthma and COPD and intensification of this therapy during exacerbations.<\/jats:p>","DOI":"10.1111\/j.1365-2222.2009.03307.x","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T19:52:20Z","timestamp":1245700340000},"page":"1700-1710","source":"Crossref","is-referenced-by-count":64,"title":["Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus"],"prefix":"10.1111","volume":"39","author":[{"given":"C. L.","family":"Skevaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. S.","family":"Spyridaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Tiniakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Xepapadaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Kafetzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. G.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,21]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"831","article-title":"Frequency, severity, and duration of rhinovirus infections in asthmatic and non\u2010asthmatic individuals","volume":"359","author":"Corne JM","year":"2002","journal-title":"a longitudinal cohort study"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.16d19.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.16d19.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/315513"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.20.6.3261"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118431"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118431"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00397.2004"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.14.9707"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.11.005"},{"key":"e_1_2_6_12_2","unstructured":"SkevakiCL PS VolonakiE PratsinisHet al.Human rhinovirus induction of fibroblast growth factor production by bronchial epithelial cells mediates stroma cell proliferation: Association with airway remodeling in asthma. XXVII Congress of the European Academy of Allergology and Clinical Immunology Barcelona 2008."},{"key":"e_1_2_6_13_2","first-page":"449","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease","volume":"361","author":"Calverley P","year":"2003","journal-title":"a randomised controlled trial"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711133372001"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-884OC"},{"key":"e_1_2_6_16_2","first-page":"616","article-title":"Combination therapy","volume":"34","author":"Edwards MR","year":"2006","journal-title":"synergistic suppression of virus-induced chemokines in airway epithelial cells"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2006.02566.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-002-0377-4"},{"key":"e_1_2_6_19_2","first-page":"291","article-title":"Housekeeping genes as internal standards","volume":"75","author":"Thellin O","year":"1999","journal-title":"use and limits"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2001.01112.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0378-4347(97)00425-8","article-title":"Automated and sensitive method for the determination of formoterol in human plasma by high\u2010performance liquid chromatography and electrochemical detection","volume":"704","author":"Campestrini J","year":"1997","journal-title":"J Chromatogr"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510140511"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M701325200"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.10.5352"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2001.1139"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.06.003"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.06.003"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.3.1437"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00109702"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.1.2006003"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-008-0048-4"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.129705"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.08.034"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.08.034"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1997.tb00670.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1997.tb00670.x"},{"key":"e_1_2_6_37_2","first-page":"1392","article-title":"Low dose inhaled budesonide and formoterol in mild persistent asthma","volume":"164","author":"O'Byrne PM","year":"2001","journal-title":"the OPTIMA randomized trial"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.2009.03307.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.2009.03307.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T23:27:16Z","timestamp":1697239636000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.2009.03307.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,21]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1365-2222.2009.03307.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.2009.03307.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,21]]}}}